Gunderson Dettmer represented client BrainChild Bio, a kids-first clinical-stage biotechnology company, in its launch by Seattle Children’s. BrainChild Bio is advancing a next-generation CAR T-cell therapy platform that weaves together synthetic technologies, including multiplex targeting and enhanced potency controls, to provide transformational therapies for tumors of the central nervous system in children. BrainChild Bio will be granted an exclusive license to novel CAR T-cell technology for CNS tumors developed at Seattle Children’s. These developments will build upon the pioneering CAR T-cell therapy and clinical translational work of Michael Jensen, M.D. and his team at Seattle Children’s Therapeutics.

Since 2012, Seattle Children’s Therapeutics has designed, manufactured and launched a robust portfolio of immunotherapy clinical trials for leukemia and lymphoma, brain tumors, and solid tumors, enrolling more than 500 patients. The launch of BrainChild Bio is a natural progression of Seattle Children’s Therapeutics’ goal to expand access to potentially life-changing therapies through collaborations with biotech companies.

In the announcement of the launch, BrainChild Bio Founder and Chief Scientific Officer Michael Jensen said, “BrainChild Bio is founded with a mission to bring the best ideas forward to push the bounds of scientific discovery in service of children with cancer. For far too long, children have been deprioritized for commercialized medicines, and families have been left without options. We are steadfast in our commitment to cracking the code of harnessing CAR T-cell technology in CNS tumors and we are uniquely positioned to do so.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Jen Lichtman and Beatrice Igne-Bianchi. 

Companies
BrainChild
Seattle Children's Therapeutics